+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oral Solid Dosage CDMO Market Size, Share & Trends Analysis Report by Product (Tablets, Capsules), Mechanism (Immediate Release, Delayed Release), Drug Potency, End-use, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 262 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098063
The Oral Solid Dosage CDMO Market was valued at USD 43.65 billion in 2024, and is projected to reach USD 63.50 billion by 2030, rising at a CAGR of 6.49%. The increasing demand for outsourcing oral solid dosage manufacturing among pharmaceutical and biopharmaceutical companies has compelled contract development and manufacturing organizations (CDMO) to expand their manufacturing facilities to support the demand of pharmaceutical companies. These expansions are made across the globe to enhance their oral solid dosage industry penetration. Furthermore, the rising demand for generic drugs is a key factor for the market growth as there are increasing numbers of generics as OSD products.

The growing number of patients suffering from chronic and infectious diseases is key factor driving demand for novel therapeutics, thereby positively influencing overall industry progression. In addition, Booming geriatric population that are highly prone to chronic diseases and high adoption rate of OSD among this population further supporting the demand for OSD. Furthermore, another factor contributing to the market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Ongoing technological advancements in the oral solid dosage CDMO market to enhance manufacturing efficiency, product quality, and regulatory compliance are positively influencing overall market growth potential. Continuous manufacturing assists seamless integration of numerous unit operations leading to streamlined production workflows and increased flexibility in manufacturing oral solid dosage forms. Moreover, innovations in techniques such as chromatography, spectroscopy, mass spectrometry, and dissolution testing enabled CDMOs to meet enhanced precision, sensitivity, & reliability in pharmaceutical analysis. Furthermore, the integration of automation, robotics, & data analytics streamlined analytical workflows, reduced turnaround times, and enhanced data integrity & compliance with regulatory standards such as Good Manufacturing Practices (GMP) & International Council for Harmonization (ICH) guidelines.

Oral Solid Dosage CDMO Market Report Highlights

  • Basd on product, the tablets segment dominated the market in 2024. The high segment growth is driven by increasing investment in research and development activities, technological advancements in manufacturing processes, innovative drug delivery options and the growing need for advanced solutions to cater to high market demand.
  • Based on the mechanism, controlled release segment held the largest market share in 2024 attributing to an improved patient compliance, enhanced efficacy & safety, and reduced frequency of administration.
  • Based on the drug potency, low potent drugs segment held the largest market share in 2024 owing to ease of development and manufacturing processes, high demand for generic drugs coupled with need for cost effective solutions, high patient population and high penetration among multiple therapeutic areas to cater effective patient outcome.
  • Based on end use, medium & small-size companies segment held the majority revenue share, accounting for over 72.34% in 2024. Growth in the segment can be attributed to the increasing number of small- & medium-sized companies outsourcing their production work to CDMOs and CMOs. Medium and small-sized pharmaceutical companies have limited resources and capabilities in formulation development, process optimization, and manufacturing of oral solid dosage forms. Thus, growing customer preference towards CDMOs for the development and manufacturing of oral solid dosage.
  • Asia-Pacific dominated the oral solid dosage CDMO market with a share of 36.76% in 2024. The outsourcing of pharmaceutical manufacturing to Asian countries, including India and China, has increased due to their lower costs and availability of potential study subjects. This has led to an increase in clinical studies conducted by pharmaceutical companies in the region. Moreover, high availability of raw materials and advanced manufacturing infrastructure will propel regional market growth.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Details of primary research
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value Chain-Based Sizing & Forecasting (Model 2)
1.7.3. QFD Model Sizing & Forecasting (Model 3)
1.7.4. Bottom-up Approach (Model 4)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. List of Abbreviations
1.11. Objectives
1.11.1. Objective 1
1.11.2. Objective 2
1.11.3. Objective 3
1.11.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Oral Solid Dosage CDMO Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Technological Advancements in Oral Solid Dosage (OSD) Forms
3.2.1.2. Expansion of Manufacturing Capacity by CMOs & CDMOs for OSD
3.2.1.3. Increasing Demand for Novel Therapies
3.2.1.4. Increasing Demand for One-Stop-Shop CMOs
3.2.2. Market Restraint Analysis
3.2.2.1. Strict Approval Criteria by Regulatory Authorities
3.2.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
3.2.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
3.3. Technology Landscape
3.3.1. Manufacturing Technology
3.3.2. Encapsulation Technology
3.3.3. Coating Technology
3.3.4. Packaging Technology
3.3.5. Analytical Technology
3.4. Pricing Model Analysis
3.5. Oral Solid Dosage Contract Manufacturing Market Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Oral Solid Dosage CDMO Market: Product Movement Analysis
4.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Tablets
4.4.1. Tablets Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4.2. Compressed Tablets
4.4.2.1. Compressed Tablets Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4.3. Orally Disintegrating Tablets (ODT)
4.4.3.1. Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4.4. Chewable Tablets
4.4.4.1. Chewable Tablets Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4.5. Bi-layer or Tri-layer Tablets
4.4.5.1. Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4.6. Sublingual or Buccal Tablets
4.4.6.1. Sublingual or Buccal Tablets Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4.7. Others
4.4.7.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Capsules
4.5.1. Capsules Market Estimates and Forecasts, 2018-2030 (USD Million)
4.5.2. Hard Gelatin Capsules
4.5.2.1. Hard Gelatin Capsules Market Estimates and Forecasts, 2018-2030 (USD Million)
4.5.3. Soft Gelatin Capsules
4.5.3.1. Soft Gelatin Capsules Market Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Powder
4.6.1. Powder Market Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Granules
4.7.1. Granules Market Estimates and Forecasts, 2018-2030 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
5.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
5.4. Immediate Release
5.4.1. Immediate Release Market Estimates and Forecasts, 2018-2030 (USD Million)
5.5. Delayed Release
5.5.1. Delayed Release Market Estimates and Forecasts, 2018-2030 (USD Million)
5.6. Controlled Release
5.6.1. Controlled Release Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
6.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2018 to 2030 (USD Million)
6.4. High Potent Drugs
6.4.1. High Potent Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Moderate Potent Drugs
6.5.1. Moderate Potent Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Low Potent Drugs
6.6.1. Low Potent Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Oral Solid Dosage CDMO Market: End Use Movement Analysis
7.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Large Size Companies
7.4.1. Large Size Companies Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Medium & Small Size Companies
7.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Others
7.6.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Oral Solid Dosage CDMO Market: Regional Estimates & Trend Analysis, by Product, by Mechanism, by Drug Potency, by End Use
8.1. Regional Dashboard
8.2. Oral Solid Dosage CDMO Market: Regional Movement Analysis
8.3. North America
8.3.1. North America Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.2. U.S.
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Canada Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.4. Mexico
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Mexico Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4. Europe
8.4.1. Europe Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. UK Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Germany Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.4. France
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. France Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.5. Italy
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Italy Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.6. Spain
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Spain Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Denmark Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Sweden Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Norway Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Asia Pacific
8.5.1. Asia Pacific Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Japan Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. China Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. India Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.5. Australia
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Australia Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Thailand Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.7. South Korea
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. South Korea Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6. Latin America
8.6.1. Latin America Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Brazil Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.3. Argentina
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Argentina Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7. Middle East & Africa
8.7.1. Middle East & Africa Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. South Africa Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Saudi Arabia Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. UAE Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Kuwait Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Company Market Share/Assessment Analysis, 2024
9.3. Company Profiles
9.3.1. Lonza
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product/Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Thermo Fisher Scientific Inc.
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product/Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Cambrex Corporation
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Product/Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Catalent Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product/Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Siegrfried Holding AG
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product/Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Recipharm AB
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Product/Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. CordenPharma International
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product/Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Boehringer Ingelheim
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Product/Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Piramal Pharma Solutions
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Product/Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Aenova Group
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Product/Service Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Almac Group
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Product/Service Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Jubilant Pharmova Limited
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Product/Service Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Delpharm
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Product/Service Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. AbbVie Contract Manufacturing
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Product/Service Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. Next Pharma AB
9.3.15.1. Company Overview
9.3.15.2. Financial Performance
9.3.15.3. Product/Service Benchmarking
9.3.15.4. Strategic Initiatives
9.3.16. Rubicon Research Pvt. Ltd.
9.3.16.1. Company Overview
9.3.16.2. Financial Performance
9.3.16.3. Product/Service Benchmarking
9.3.16.4. Strategic Initiatives
9.3.17. Quotient Sciences
9.3.17.1. Company Overview
9.3.17.2. Financial Performance
9.3.17.3. Product/Service Benchmarking
9.3.17.4. Strategic Initiatives
9.3.18. Almac Group
9.3.18.1. Company Overview
9.3.18.2. Financial Performance
9.3.18.3. Product/Service Benchmarking
9.3.18.4. Strategic Initiatives
9.3.19. SPI Pharma
9.3.19.1. Company Overview
9.3.19.2. Financial Performance
9.3.19.3. Product/Service Benchmarking
9.3.19.4. Strategic Initiatives
9.3.20. DPT Laboratories Ltd.
9.3.20.1. Company Overview
9.3.20.2. Financial Performance
9.3.20.3. Product/Service Benchmarking
9.3.20.4. Strategic Initiatives
9.3.21. Alcami Corporation
9.3.21.1. Company Overview
9.3.21.2. Financial Performance
9.3.21.3. Product/Service Benchmarking
9.3.21.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 4 Global Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 5 Global Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 6 Global Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 7 Global Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 8 Global Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 9 Global Oral Solid Dosage CDMO Market, by Region, 2018-2030 (USD Million)
Table 10 North America Oral Solid Dosage CDMO Market, by Country, 2018-2030 (USD Million)
Table 11 North America Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 12 North America Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 13 North America Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 14 North America Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 15 North America Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 16 North America Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 17 U.S Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 18 U.S Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 19 U.S Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 20 U.S Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 21 U.S Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 22 U.S Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 23 Canada Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 24 Canada Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 25 Canada Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 26 Canada Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 27 Canada Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 28 Canada Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 29 Mexico Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 30 Mexico Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 31 Mexico Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 32 Mexico Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 33 Mexico Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 34 Mexico Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 35 Europe Oral Solid Dosage CDMO Market, by Country, 2018-2030 (USD Million)
Table 36 Europe Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 37 Europe Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 38 Europe Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 39 Europe Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 40 Europe Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 41 Europe Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 42 Germany Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 43 Germany Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 44 Germany Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 45 Germany Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 46 Germany Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 47 Germany Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 48 UK Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 49 UK Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 50 UK Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 51 UK Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 52 UK Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 53 UK Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 54 France Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 55 France Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 56 France Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 57 France Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 58 France Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 59 France Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 60 Italy Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 61 Italy Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 62 Italy Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 63 Italy Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 64 Italy Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 65 Italy Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 66 Spain Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 67 Spain Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 68 Spain Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 69 Spain Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 70 Spain Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 71 Spain Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 72 Denmark Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 73 Denmark Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 74 Denmark Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 75 Denmark Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 76 Denmark Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 77 Denmark Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 78 Sweden Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 79 Sweden Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 80 Sweden Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 81 Sweden Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 82 Sweden Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 83 Sweden Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 84 Norway Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 85 Norway Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 86 Norway Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 87 Norway Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 88 Norway Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 89 Norway Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 90 Asia Pacific Oral Solid Dosage CDMO Market, by Country, 2018-2030 (USD Million)
Table 91 Asia Pacific Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 92 Asia Pacific Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 93 Asia Pacific Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 94 Asia Pacific Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 95 Asia Pacific Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 96 Asia Pacific Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 97 China Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 98 China Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 99 China Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 100 China Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 101 China Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 102 China Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 103 Japan Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 104 Japan Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 105 Japan Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 106 Japan Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 107 Japan Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 108 Japan Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 109 India Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 110 India Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 111 India Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 112 India Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 113 India Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 114 India Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 115 South Korea Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 116 South Korea Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 117 South Korea Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 118 South Korea Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 119 South Korea Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 120 South Korea Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 121 Australia Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 122 Australia Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 123 Australia Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 124 Australia Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 125 Australia Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 126 Australia Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 127 Thailand Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 128 Thailand Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 129 Thailand Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 130 Thailand Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 131 Thailand Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 132 Thailand Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 133 Latin America Oral Solid Dosage CDMO Market, by Country, 2018-2030 (USD Million)
Table 134 Latin America Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 135 Latin America Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 136 Latin America Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 137 Latin America Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 138 Latin America Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 139 Latin America Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 140 Brazil Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 141 Brazil Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 142 Brazil Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 143 Brazil Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 144 Brazil Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 145 Brazil Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 146 Argentina Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 147 Argentina Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 148 Argentina Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 149 Argentina Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 150 Argentina Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 151 Argentina Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 152 Middle East & Africa Oral Solid Dosage CDMO Market, by Country, 2018-2030 (USD Million)
Table 153 Middle East & Africa Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 154 Middle East & Africa Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 155 Middle East & Africa Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 156 Middle East & Africa Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 157 Middle East & Africa Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 158 Middle East & Africa Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 159 South Africa Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 160 South Africa Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 161 South Africa Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 162 South Africa Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 163 South Africa Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 164 South Africa Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 165 Saudi Arabia Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 166 Saudi Arabia Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 167 Saudi Arabia Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 168 Saudi Arabia Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 169 Saudi Arabia Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 170 Saudi Arabia Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 171 UAE Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 172 UAE Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 173 UAE Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 174 UAE Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 175 UAE Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 176 UAE Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
Table 177 Kuwait Oral Solid Dosage CDMO Market, by Product, 2018-2030 (USD Million)
Table 178 Kuwait Oral Solid Dosage CDMO Market, by Tablets, 2018-2030 (USD Million)
Table 179 Kuwait Oral Solid Dosage CDMO Market, by Capsules, 2018-2030 (USD Million)
Table 180 Kuwait Oral Solid Dosage CDMO Market, by Mechanism, 2018-2030 (USD Million)
Table 181 Kuwait Oral Solid Dosage CDMO Market, by Drug Potency, 2018-2030 (USD Million)
Table 182 Kuwait Oral Solid Dosage CDMO Market, by End Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Information Procurement
Figure 2 Primary Research Pattern
Figure 3 Market Research Approaches
Figure 4 Value Chain-Based Sizing & Forecasting
Figure 5 Market Formulation & Validation
Figure 6 Oral Solid Dosage CDMO, Market Segmentation
Figure 7 Market Driver Relevance Analysis (Current & Future Impact)
Figure 8 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 10 Porter’s Five Forces Analysis
Figure 11 Regional Marketplace: Key Takeaways
Figure 12 Global Oral Solid Dosage CDMO, for Tablets, 2018-2030 (USD Million)
Figure 13 Global Oral Solid Dosage CDMO, for Compressed Tablets, 2018-2030 (USD Million)
Figure 14 Global Oral Solid Dosage CDMO, for Orally Disintegrating Tablets (ODT), 2018-2030 (USD Million)
Figure 15 Global Oral Solid Dosage CDMO, for Chewable Tablets, 2018-2030 (USD Million)
Figure 16 Global Oral Solid Dosage CDMO, for Bi-layer or Tri-layer Tablets, 2018-2030 (USD Million)
Figure 17 Global Oral Solid Dosage CDMO, for Sublingual or Buccal Tablets, 2018-2030 (USD Million)
Figure 18 Global Oral Solid Dosage CDMO, for Others, 2018-2030 (USD Million)
Figure 19 Global Oral Solid Dosage CDMO, for Hard Gelatin Capsules, 2018-2030 (USD Million)
Figure 20 Global Oral Solid Dosage CDMO, for Soft Gelatin Capsules, 2018-2030 (USD Million)
Figure 21 Global Oral Solid Dosage CDMO, for Immediate Release, 2018-2030 (USD Million)
Figure 22 Global Oral Solid Dosage CDMO, for Delayed Release, 2018-2030 (USD Million)
Figure 23 Global Oral Solid Dosage CDMO, for Controlled Release, 2018-2030 (USD Million)
Figure 24 Global Oral Solid Dosage CDMO, for High Potent Drugs, 2018-2030 (USD Million)
Figure 25 Global Oral Solid Dosage CDMO, for Moderate Potent Drugs, 2018-2030 (USD Million)
Figure 26 Global Oral Solid Dosage CDMO, for Low Potent Drugs, 2018-2030 (USD Million)
Figure 27 Global Oral Solid Dosage CDMO, for Large Size Companies, 2018-2030 (USD Million)
Figure 28 Global Oral Solid Dosage CDMO, for Medium & Small Size Companies, 2018-2030 (USD Million)
Figure 29 Global Oral Solid Dosage CDMO, for Others, 2018-2030 (USD Million)
Figure 30 Regional Outlook, 2023 & 2030
Figure 31 North America Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 32 U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 33 Canada Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 34 Mexico Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 35 Europe Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 Germany Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 37 UK Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 38 France Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 39 Italy Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 40 Spain Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 Denmark Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 42 Sweden Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 43 Norway Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 44 Asia Pacific Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 45 Japan Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 46 China Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 47 India Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 48 Australia Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 49 South Korea Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 50 Thailand Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 Latin America Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 52 Brazil Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 53 Argentina Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 54 Middle East and Africa Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 South Africa Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 56 Saudi Arabia Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 UAE Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 58 Kuwait Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018-2030 (USD Million)

Companies Mentioned

The major companies featured in this Oral Solid Dosage CDMO market report include:
  • Lonza
  • Thermo Fisher Scientific Inc.
  • Cambrex Corporation
  • Catalent Inc.
  • Siegrfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Boehringer Ingelheim
  • Piramal Pharma Solutions
  • Aenova Group
  • Almac Group
  • Jubilant Pharmova Limited
  • Delpharm
  • AbbVie Contract Manufacturing
  • Next Pharma AB
  • Rubicon Research Pvt. Ltd.
  • Quotient Sciences
  • SPI Pharma
  • DPT Laboratories Ltd.
  • Alcami Corporation

Table Information